Jinan Hi-tech Development(SH:600807) Xin Lang Cai Jing·2025-07-15 08:55Core Viewpoint - Jinan High-tech Development Co., Ltd. expects a net loss of approximately 45 million yuan for the first half of 2025, indicating an expanded loss compared to the same period last year [1][2]. Financial Performance - The company's net profit attributable to shareholders for the same period last year was -29.63 million yuan, showing a significant increase in losses [2]. - In 2024, the company's operating revenue was 372 million yuan, a decrease of 48.0% year-on-year, while the net profit attributable to shareholders worsened from -95.10 million yuan in 2023 to -806 million yuan [5]. Business Operations - The main business of the company is in in vitro diagnostics, with additional involvement in trade, real estate, and property services [6]. - In 2024, the revenue from the in vitro diagnostics business was 160 million yuan, a decline of 56.51% compared to the previous year, with a decrease in operating costs by 50.17% and a drop in gross margin by 9.68% [6]. - The company attributes the decline in its in vitro diagnostics revenue to the overall market environment and its own business operations, particularly the performance of its subsidiary, Aikwei Biomedical [6]. Legal Issues - The company has disclosed multiple updates regarding litigation progress throughout the year, which have contributed to the negative net profit, primarily due to contractual negligence and debt disputes, leading to estimated compensation losses of approximately 40 million yuan [5].